ENDPOINTS NEWS11h
Yuhan ends can­cer project with J&J as it signs API deal with Gilead on HIV drugs
Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...
FiercePharma11h
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Yuhan, Janssen halt next-gen cancer drug collaboration
South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...
Korea Joongang Daily on MSN1d
Yuhan inks $80.9 million deal with Gilead Sciences for HIV ingredients
Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...